Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention

Part of paid clinical trials in Eugene, Oregon.

Sponsor
Chestnut Health Systems
Study ID
NCT06852170
Status
Recruiting
Apply to this trial

Conditions

  • Decision Making
  • Decision Making, Shared
  • Implementation Science
  • Organizations
  • Policy
  • Substance Abuse
  • Substance-related Disorders

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Co-Design Sessions (CDS) — OTHER
    CDS uses principles and activities from Liberating Structures (LS) and Group Model Building (GMB). Each method uses semi-structured processes for engaging partners to collaborate with one another and address complex problems. Example activities and discussions include: identifying a shared vision for how data can inform decisions related to substance use service delivery and overdose prevention; identifying relevant data that should be disseminated; identifying decisions to be supported with data. Methods from human-centered design - an approach for developing products that are useful and easy to use - will be used to refine data products developed by the study team so that the data products are acceptable and useful to end users. Together, these three methods (Liberating Structures, group model building, human-centered design) will be used to engage partners to iteratively co-design products for disseminating data back to partners to inform their daily substance use service delivery.
  • Data products — OTHER
    Data products disseminate localized data from local, state, or regional-level data sources to local (i.e., county) decision makers to inform their daily decision-making. Data products in counties assigned to CDS will receive fully tailored data products, while no-CDS counties will receive standardized data products. A suite of data products will be made available to inform diverse decisions by a variety of end users. Data products will be identified and prioritized during CDS, but may include reports, policy briefs, journey maps, and technical assistance for data interpretation.

Study Details

Oregon's decision makers (e.g., community service providers, public health, justice, advocacy groups, payers) are calling for comprehensive, current, and trusted data to inform how they allocate resources to improve substance use services and mitigate the growing opioid and methamphetamine epidemics in their state. Consistent with the HEAL Data2Action call for Innovation projects that drive action with data in real-world settings, this study will refine and test the impact of a novel implementation strategy to engage cross- sector decision makers and make data that they identify as relevant to their decisions available to them in easy- to-use products. The proposed study aims to not only address critical knowledge gaps regarding how and when data can inform impactful, transparent decision-making, but to provide decision makers with the data that they need to achieve community-wide substance use prevention and treatment goals, including the increased delivery of high-quality, evidence-informed, services and the prevention of overdoses.

Key Dates

Start date
Feb 6, 2025
Status verified
Mar 2026
Primary completion
Jun 1, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
341 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: CDS
    This group will participate in 4 CDS to co-design and tailor data products with the study team. They will receive fully tailored Data Products at T3 or T4, depending on wedge assignment.
  • Experimental: No CDS
    This group will not participate in CDS. They will receive standardized data products at T3 or T4, depending on wedge assignment.

Primary Outcome Measure

Community Engagement Survey [ Time Frame: Measurement will occur at five timepoints: baseline, around 15 months post-baseline, around 18 months post-baseline, around 30 months post-baseline, around 42 months post-baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Chestnut Health SystemsEugeneOregon97401
Gracelyn Cruden, PhD, MA
[email protected]
8435139928
Amanda J Broughton
[email protected]
Gracelyn Cruden, PhD, MA (PRINCIPAL_INVESTIGATOR)

Find similar trials in Eugene, OR

By research site
Chestnut Health Systems· Eugene, OR

Related Studies